Loading...
•
Dec 31, 2019
NeoGenomics Q4 2019 Earnings Report
NeoGenomics experienced substantial revenue growth and strategic advancements.
Key Takeaways
NeoGenomics reported a strong Q4 2019, with a 40% increase in consolidated revenue to $106.9 million. The company saw growth in both Clinical and Pharma Services, driven by market share gains and strategic investments. Net income increased significantly, and the company issued positive financial guidance for 2020.
Consolidated revenue increased by 39.7% reaching $106.9 million.
Clinical Services revenue grew by 41.7% to $93.4 million.
Pharma Services revenue increased by 27.5% to $13.5 million.
Pharma Services backlog increased by 31.8% to $130.3 million.
Forward Guidance
The Company issued 2020 guidance and expects consolidated revenue between $464 million and $474 million, net income between $8 million and $13 million, and Adjusted EBITDA between $60 million and $65 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...